Dry Powder Inhalers Market
Number of pages: 100 | Report Format: PDF | Published date: April 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 7.73 billion |
|
Revenue Forecast in 2031 |
US$ 11.40 billion |
|
Growth Rate |
4.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global dry powder inhalers market was valued at US$ 7.73 billion in 2022 and is expected to register a revenue CAGR of 4.4% to reach US$ 11.40 billion by 2031.
Dry Powder Inhalers Market Fundamentals
The dry powder inhalers (DPIs) market refers to the global market for medical devices that deliver dry powdered medications directly into the lungs to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. DPIs offer several advantages over traditional inhalation devices, such as metered-dose inhalers (MDIs) and nebulizers, including ease of use, portability, and cost-effectiveness. Several types of DPIs are available on the market, including single-dose DPIs, multi-dose DPIs, etc. Some major DPI market players include GlaxoSmithKline, Novartis AG, AstraZeneca, Boehringer Ingelheim, and Teva Pharmaceutical Industries. These companies are investing heavily in research and development to develop new and improved DPIs and in marketing & distribution to expand their reach in the global market. The dry powder inhalers market is expected to grow in the coming years, driven by factors such as the increasing prevalence of respiratory diseases, the rising demand for convenient and effective inhalation devices, and the emergence of new & innovative ones DPI products.
[868678]
Dry Powder Inhalers Market Dynamics
The rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis has driven the demand for dry powder inhalers. According to the National Centre for Health Statistics, people over 85 had the highest prevalence of physician ambulatory-care visits for respiratory disorders. In contrast, those between the ages of 75 & 84 and 65 & 74 have, respectively, 57% and 85% lower rates. Dry powder inhalers effectively deliver medication directly to the lungs, which is important for managing these diseases. The development of more advanced DPI technology has also been driving the revenue growth of the global dry powders market. For example, new DPIs have been designed to be more user-friendly and easier to use, increasing patient compliance and improving treatment outcomes. DPIs are highly portable and convenient, making them increasingly popular among patients who want to manage their respiratory diseases on the go. The ease of use and portability of DPIs has also made them a popular choice for patients in developing countries with limited access to healthcare. The trend toward personalized medicine has also been driving the revenue growth of the DPI market. DPIs can be customized to deliver specific dosages and formulations of medication, which is important for patients with different needs and medical conditions. With the aging of the population in many countries, the demand for respiratory disease management is expected to grow. As a result, the global dry powder inhalers market is expected to continue to expand during the forecast period. Overall, the global dry powder inhalers market revenue is expected to continue to grow due to these factors as more people recognize the benefits of this type of drug delivery device for respiratory disease management.
However, the global dry powder inhaler market faces challenges such as regulatory hurdles, high development costs, and competition from other inhalation devices such as metered-dose inhalers and nebulizers.
Dry Powder Inhalers Market Ecosystem
The global dry powder inhalers market is analyzed from four perspectives: type, application, distribution channel, and region.
Dry Powder Inhalers Market by Type
[867876]
Based on type, the global dry powder inhalers market is segmented into single-dose dry powder inhalers and multi-dose dry powder inhalers.
The single-dose dry powder inhalers segment accounted for the largest revenue share in the global dry powder inhaler devices market. Due to their higher acceptance and larger market revenue than other product types, single-dose dry powder inhalers retained the largest market revenue share. Due to the product’s affordability and the ease with which developing countries with moderate or poor healthcare expenditure sectors can choose these dry powder inhalers, the market revenue is expected to maintain its dominance during the forecast period.
The multi-dose dry powder inhaler segment is expected to account for a large revenue growth during the forecast period since the usage of multi-dose dry powder inhalers has been on the upswing owing to the fact that there is an increasing demand and utilization of dry powder inhalers worldwide. Additionally, as these inhalers are affordable for many locations, including vehicles, residences, and job sites, their demand is expected to increase going forward to expand the segment’s revenue share during the forecast period.
Dry Powder Inhalers Market by Application
Based on application, the global dry powder inhalers market is segmented into chronic obstructive pulmonary disease, pulmonary arterial hypertension, asthma, and others.
The asthma segment accounts for the largest global dry powder inhalers market revenue share. This is a result of global air pollution levels rising and an increase in asthma cases, particularly in wealthy nations. According to the American Asthma and Allergy Foundation, in 2020, 42.7% of children aged eighteen and under who had the condition recorded one or more asthma attacks.
Dry Powder Inhalers Market by Distribution Channel
Based on the distribution channel, the dry powder inhalers market is segmented into hospital pharmacies, online pharmacies, and drug stores.
The hospital pharmacies segment accounted for the largest global dry powder inhaler market revenue share. Because of robust distribution channels and rising doctor adoption preferences, the large share can be attributed to the revenue growth in the number of hospital pharmacies in nations like Brazil, India, and China, along with the rising number of prescriptions for dry powder inhalers by hospitals. These trends are expected to affect market revenue growth during the forecast period positively.
The online pharmacies segment is expected to record a high revenue CAGR during the forecast period. Due to the improvement in the usability of retail e-commerce websites, the rapid progress seen in internet penetration, and the rise in popularity of e-commerce shopping portals over the past ten years, the online pharmacy industry is expected to experience large revenue growth.
Dry Powder Inhalers Market by Region
Based on region, the global dry powder inhalers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounts for the largest global dry powder inhalers market revenue share. This is due to a solid infrastructure, significant market players, and ongoing investments in R&D activities. The growth of the US dry powder inhaler devices market is further aided by the increased prevalence of asthma and other respiratory disorders and the growing elderly population. GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceutical Industries are a few of the leading companies in the North American DPI industry. To release cutting-edge DPI gadgets in the market, these businesses are heavily putting money into research and development. Overall, the North American DPI market is expected to remain highly competitive, with companies focusing on developing devices that are easy to use, effective, and affordable for patients with respiratory diseases.
Europe accounts for the second largest global dry powder inhalers market revenue share. Dry powder inhalers are in high demand across the board in Europe due to changes in lifestyle and an increase in allergies and illnesses among the populace. Workers’ respiratory conditions are more common now due to industrialization and excessive chemical use, which has sparked market revenue growth.
During the forecast period, Asia Pacific is expected to record a high revenue CAGR in the global dry powder inhalers market. This sizable share of revenue is due to the factors such as increasing demand for efficient drug delivery systems, rising healthcare expenditure, and growing awareness about the benefits of inhalation therapy over traditional oral medication. Japan is expected to account for the largest market revenue, owing to the high prevalence of respiratory diseases and a large geriatric population. The rising prevalence of respiratory disorders and the rising demand for inhaled drugs will likely drive significant revenue growth in China and India. In addition to these elements, market players’ increased emphasis on R&D initiatives, the launch of novel products, and the expanding use of digital technologies in healthcare are anticipated to fuel the revenue growth of the dry powder inhalers market in the Asia Pacific region.
Dry Powder Inhalers Market Competitive Landscape
The prominent players operating in the global dry powder inhalers market are:
Dry Powder Inhalers Market Strategic Developments
The expected size of the global dry powder inhalers market in 2031 is US$ 11.40 billion.
The expected revenue CAGR for the global dry powder inhalers market is 4.4% during the forecast period.
GlaxoSmithKline plc, AstraZeneca Plc, 3M Company, Boehringer Ingelheim GmbH, and Chiesi Farmaceutici S.p.A. are some of the major key players operating in the global dry powder inhalers market.
Asia Pacific is expected to register a high revenue CAGR in the global dry powder inhalers market.
The regulatory requirements for DPIs are quite stringent, which can increase the time and cost of developing new products and limit the number of products available in the market. DPIs require a certain level of manual dexterity to be used effectively, which can limit their use in certain patient populations, such as elderly individuals or those with limited mobility.
*Insights on financial performance are subject to the availability of information in the public domain